Sorafenib Drug: Reprieve For Primary Liver Cancer Patients

by Tanya Thomas on  June 30, 2008 at 9:23 AM Drug News   - G J E 4
Sorafenib Drug: Reprieve For Primary Liver Cancer Patients
According to recent studies, a drug "sorafenib" can improve the chances of survival among patients with primary liver cancer.

The study led by the Barcelona Hospital Clinic has shown that patients with primary hepatocarcinomas (liver tumours) taking the drug are likely to live 40 pct more on average compared to those not taking it.

Hepatocarcinoma is the most frequent hepatic tumour, fifth in overall worldwide cancer rates and the third cause of cancer deaths in the world

Sorafenib has been the first to demonstrate its efficacy and the European Medicines Agency has recently authorised its use for this tumour, given that it can prolong patient survival at the cost of some side effects, which, in 80% of cases, are manageable with a number of preventative or therapeutic measures.

The study also included researchers from the University Hospital of the University of Navarra, together with other hospitals in Spain.

Source: ANI

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like